Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02294851 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02294851 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 65 participants.
The verdict
NCT02294851, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo controlled, single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
Interventions
- DRUG BMS-986168
- DRUG BMS-986168 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2016-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02294851
The ClinicalTrials.gov registry entry for NCT02294851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986168 is the first listed.
NCT02294851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02294851 about?
NCT02294851 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects". This is a randomized, double-blind, placebo controlled, single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
What is the current status of trial NCT02294851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2014-12-31. Estimated completion is 2016-04-30.
What interventions are being tested in trial NCT02294851?
The interventions under investigation include: BMS-986168 (DRUG), BMS-986168 Placebo (DRUG).
Who is sponsoring clinical trial NCT02294851?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.